Haloperidol Crescent Pharma (Haloperidol)

Haloperidol Crescent Pharma is indicated for the treatment of several psychiatric disorders where dopamine blockade is therapeutic.

• Schizophrenia, including acute exacerbations and maintenance therapy.
• Acute psychotic episodes associated with mood disorders or substance use.
• Tourette syndrome, particularly for reducing motor and vocal tics.
• Severe agitation or aggression in hospitalized patients when rapid control is needed.
• Adjunctive therapy for other conditions as determined by a qualified clinician.

Side effects of haloperidol may vary in frequency and severity; they are typically categorized as common or serious.

Common

• Drowsiness, fatigue, or sedation.
• Extrapyramidal symptoms such as tremor, rigidity, or akathisia.
• Dry mouth, constipation, or blurred vision.

Serious

• Neuroleptic malignant syndrome, a potentially life‑threatening reaction.
• Tardive dyskinesia, characterized by involuntary movements.
• Significant cardiac effects, including QT interval prolongation.

Before initiating Haloperidol Crescent Pharma, clinicians should assess patient history and monitor for specific risks associated with antipsychotic therapy.

• Evaluate cardiovascular status, especially for QT prolongation risk.
• Review personal or family history of movement disorders.
• Assess liver and renal function, adjusting therapy as needed.
• Use caution in patients with a history of seizures or electrolyte imbalance.
• Monitor for signs of neuroleptic malignant syndrome during treatment.
• Consider pregnancy and lactation status; safety data are limited.

Haloperidol can interact with other medications, influencing its effectiveness or increasing adverse effects; interactions are grouped by clinical relevance.

Avoid

• Concurrent use with other dopamine antagonists or high‑potency antipsychotics.
• Strong CYP3A4 inhibitors such as ketoconazole or clarithromycin.

Use with caution

• CYP3A4 inducers like carbamazepine or rifampin, which may lower haloperidol levels.
• Medications that prolong the QT interval, including certain antiarrhythmics and fluoroquinolones.
• Central nervous system depressants, for example benzodiazepines or opioids.